MEIS1 rs11693221: Sleep and Restless Legs Genetics
The genetic variant rs11693221 is a single nucleotide polymorphism located in the 3' untranslated region of the MEIS1 gene on chromosome 2. Large-scale genome-wide association studies have identified variants within this locus as risk factors for restless legs syndrome, periodic limb movements in sleep, and related sleep disturbances. Carrying the minor allele is associated with a modest statistical increase in susceptibility to these sleep-related movement traits.
What each genotype means
Typical genetic risk profile
This genotype represents the common version of the MEIS1 variant. Research indicates this version is not associated with the increased risk for restless legs syndrome or insomnia symptoms observed with the alternative allele.
This is the most common genotype in most global populations, carried by the majority of individuals.
Increased risk association
Carrying one copy of the A allele is associated with a statistically higher likelihood of experiencing restless legs syndrome and insomnia symptoms compared to those without it. This association is based on population-level data, and individual risk is influenced by many other genetic and environmental factors.
This genotype is found in approximately 25-35% of individuals of European ancestry.
Elevated risk association
Carrying two copies of the A allele is associated with a higher statistical risk for restless legs syndrome and insomnia symptoms compared to those with one or no copies. While this variant is a well-documented genetic signal for these traits, it does not guarantee the development of symptoms, as sleep health is complex and multifactorial.
This genotype is less common, typically found in roughly 3-5% of individuals of European ancestry.
Genomic Context and the rs11693221 Variant
The rs11693221 variant is a common single nucleotide polymorphism mapped to chromosome 2 within the 3' untranslated region (3' UTR) of the MEIS1 gene. Non-coding variants situated in regulatory domains such as the 3' UTR frequently play functional roles by influencing mRNA stability, cellular localization, or microRNA binding efficiency. Rather than directly changing an amino acid sequence, variants like rs11693221 typically act as regulatory markers or exist in tight linkage disequilibrium with other non-coding sequence changes that alter MEIS1 expression levels across different tissues.
Biological Role of the MEIS1 Gene
MEIS1 encodes the Meis homeobox 1 protein, an essential transcription factor that plays fundamental roles during embryonic development, neurogenesis, and limb patterning. In the central nervous system, MEIS1 has been implicated in pathways governing cellular differentiation and central iron homeostasis. Mechanistic studies have demonstrated that alterations in MEIS1 expression perturb the regulation of key iron-binding proteins such as ferritin and the divalent metal transporter 1 (DMT1). Because brain iron deficiency is a well-established pathophysiological hallmark of restless legs syndrome, MEIS1 regulation is thought to impact neurochemical pathways including dopamine synthesis and signaling.
Research Associations and Strength of Evidence
The MEIS1 genomic region represents one of the most robust and consistently replicated genetic loci identified in sleep medicine, first highlighted in early genome-wide association studies of restless legs syndrome (RLS) and periodic limb movement in sleep (PLMS). Variants at this locus have also appeared in broad GWAS analyses evaluating insomnia symptoms. However, current evidence indicates that rs11693221 itself carries limited direct clinical validation compared to the overall locus. Furthermore, follow-up sleep cohort studies suggest the association with insomnia may largely reflect secondary sleep disruption stemming from underlying RLS or nocturnal motor restlessness rather than an independent insomnia phenotype.
Population Distribution and Allele Patterns
The minor A allele of rs11693221 occurs at an estimated frequency of approximately 15% to 20% in populations of European ancestry, meaning that a notable fraction of individuals carry at least one copy. Genotypic frequencies reflect this distribution, with the homozygous reference genotype (GG) being the most common, followed by the heterozygous genotype (AG), while the homozygous risk genotype (AA) is observed in a smaller subset of the population. Allele frequencies often differ across global populations, highlighting the necessity of evaluating polygenic findings within relevant ancestral backgrounds.
Clinical Interpretation and Practical Application
Identifying an rs11693221 genotype provides educational insight into polygenic predispositions but cannot diagnose or rule out any medical condition. Restless legs syndrome is a complex multifactorial trait influenced by peripheral iron status, kidney function, pregnancy, medications, and numerous environmental factors. Having an associated genotype does not guarantee the development of sleep disturbances, nor does a standard genotype grant immunity. Individuals experiencing persistent sleep difficulties, daytime fatigue, or uncomfortable crawling sensations in the limbs should consult a qualified healthcare professional for formal clinical evaluation.
How common is this variant?
The minor A allele occurs at a frequency of approximately 15% to 20% in populations of European ancestry. As a result, the majority of European-ancestry individuals carry the GG genotype, while the AA genotype is relatively uncommon.
Frequently asked questions
Does having the rs11693221 risk allele mean I will get restless legs syndrome?
No. Genetic variants identified in genome-wide studies confer modest shifts in statistical susceptibility rather than definitive outcomes. Restless legs syndrome depends heavily on systemic iron levels, environmental triggers, and many other genetic factors.
How does the MEIS1 gene influence sleep and movement?
MEIS1 produces a regulatory protein involved in neural development and cellular iron transport. Disruption of normal MEIS1 expression may alter iron handling in the brain, which can indirectly influence dopamine pathways essential for motor control during rest.
Can rs11693221 explain chronic insomnia?
While some insomnia GWAS datasets flag MEIS1, targeted clinical studies indicate the association is largely driven by secondary sleep disruption from limb discomfort or periodic movements rather than isolated chronic insomnia.
Can a medical provider use this SNP test to prescribe RLS medications?
No. Restless legs syndrome is diagnosed through clinical history and symptom assessment rather than genetic sequencing. You should always discuss symptoms, medication choices, and dosing directly with your physician or pharmacist.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11693221?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in MEIS1
This intronic regulatory variant in MEIS1 is a primary risk locus for restless legs syndrome, influencing gene expression in the developing telencephalon.
A fine-mapped regulatory variant within the MEIS1 locus associated with restless legs syndrome and periodic limb movements during sleep.
This intronic variant in the MEIS1 gene is one of the most robustly replicated genetic risk factors for restless legs syndrome (RLS) and periodic limb movements of sleep.
Intronic SNP strongly predisposing individuals to Restless Legs Syndrome and periodic limb movements during sleep.
Intronic regulatory variant within MEIS1 strongly implicated in periodic limb movements during sleep and restless legs syndrome etiology.
Non-coding regulatory variant in MEIS1 that is strongly associated with periodic limb movements during sleep and symptom severity in restless legs syndrome.